ASCRS 2025: New research findings highlight the surprising impact of hyperosmolarity
Lisa Nijm, MD, says preoperative osmolarity testing can help clinicians manage patient expectations and improve surgical results.
Palatin releases updated results from responder analyses of phase 3 Melody-1 trial in dry eye
Responder analysis was conducted to evaluate the percentage of patients achieving complete symptom resolution across 13 pre-specified symptom endpoints.
Study identifies key biomarkers for aflibercept response in diabetic macular edema
Brazilian researchers reveal how choroidal thickness influences treatment response in diabetic macular edema, enhancing personalized therapy strategies.
ASCRS 2025: Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
The retrospective study assessed corneal cross-linking complications at Wills Eye Hospital from 2018 to 2023.
ASCRS 2025: Maanasa Indaram, MD, offers guidance for general anesthesia in pediatric corneal crosslinking
Regeneron to highlight real-world efficacy of aflibercept 8 mg (EYLEA HD) in wAMD, DME, and DR
The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting from May 4 to 8 in Salt Lake City.
Human papillomavirus possibly linked to thyroid eye disease
New research links HPV to thyroid eye disease, suggesting viral infection may trigger immune responses through molecular mimicry, impacting diagnosis and treatment.
ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
Use of the LENSAR Ally femtosecond laser for arcuate incisions was associated with improved early visual outcomes and reduced need for postoperative adjustments in premium IOL patients.
ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Red light therapy in children with myopia
Chinese researchers reveal that low-level red light therapy may control myopia in children but raises concerns about retinal damage and cone density reduction.
ASCRS 2025: A museum exhibit inspired an award-winning alternative to traditional blepharoplasty
Patricia Buehler, MD, MPH, presented a poster and two patient films at the ASCRS annual meeting, focused on minimally-invasive blepharoplasty device Ziplyft (Osheru).
ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
AI’s use in diagnostic tools, surgical guidance, and its ethical considerations in ophthalmology are transforming the field
ASCRS 2025: Rotational stability and outcomes with 'monofocal plus' toric IOL with Gregory Moloney, FRANZCO, FRCSC
A study reports minimal rotation and improved near vision following implantation of the Eyhance toric lens.
ASCRS 2025: A UK study demonstrates the benefit of endoscopic cyclophotocoagulation for patients with POAG and cataracts
Sheng Lim, MD, FRCOphth, discussed the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP.
ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Data show excellent refractive stability, strong visual acuity across all distances, and contrast sensitivity comparable to monofocal IOLs.
ASCRS 2025: Near vision victories and distance vision surprises with a presbyopia-correcting IOL
Alex Hacopian, MD, speaks about patient-reported outcomes from a presbyopia-correcting IOL at the 2025 ASCRS annual meeting.
Allotex appoints Michael Mrochen as CEO
Allotex launches its innovative eye implant for near vision restoration, appointing Michael Mrochen as CEO to drive global expansion and market access.
Q&A: Continuum of care, the evolution of cornea, cataract, and refractive surgery
George O. Waring IV, MD, FACS, discusses the “vision for a lifetime” approach and how modern advancements allow tailored treatments for every stage of eye maturity.
NIH researchers use AI to enhance retinal imaging
Scientists enhance eye imaging with AI, achieving high-resolution views of retinal cells, potentially revolutionizing disease detection and monitoring in clinics.
Scientists create a color the human eye has never seen before
Researchers unveil a groundbreaking method to stimulate retinal M cells, creating a new color, "olo," beyond human vision's natural limits.
ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Majmudar encourages young surgeons to seek hands-on experience early and often, stressing the importance of real-world practice beyond the classroom.
ASCRS 2025: Cryopreserved amniotic membrane could change how we approach neurotrophic keratitis
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
ASCRS 2025: Oluwatosin U. Smith, MD, champions early intervention and innovative glaucoma technologies
Explore innovative glaucoma treatments and technologies, including AI, home monitoring, and new surgical options, to enhance patient care.
ASCRS 2025: Companies share preview of data and presentations scheduled for 2025 annual meeting
Discover groundbreaking advancements in eye care at ASCRS 2025, featuring innovative technologies and research from leading ophthalmology companies.
Positive topline results from phase 2 VVN461 trial for non-infectious anterior uveitis
VivaVision Biotech reveals promising phase 2 trial results for VVN461, a new treatment for Non-Infectious Anterior Uveitis, showcasing safety and efficacy.
NEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325
New research reveals UBX1325's potential to significantly improve vision in diabetic macular edema patients, offering hope for innovative retinal therapies.
Neuro-ophthalmologic evaluation crucial in differentiating benign from life-threatening diplopia
Canadian investigators urged quick neuro-ophthalmologic referrals to limit the progress of life- and vision-threatening conditions.
(Part 2) From ophthalmology’s lockdown to lasting change: The pandemic habits that stuck
From revised patient flow to smarter tech adoption, ophthalmologists share which changes from 2020 have become cornerstones of modern care—and how they’re preparing for the next big disruption
(Part 1) From ophthalmology’s lockdown to lasting change: Five Aprils ago
Ophthalmologists reflect on the transformative impact of COVID-19, highlighting adaptations in patient care, safety protocols, and the rise of telemedicine.
ENTOD Pharmaceuticals announces CDSCO approval of 0.05% atropine drops (Myatro XL)
ENTOD Pharmaceuticals launches Myatro XL, a 0.05% atropine eye drop, to effectively slow myopia progression in children, available by prescription in 2025.
